Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy最新文献

{"title":"Triglycerides and HDL Cholesterol Mediate the Association Between Waist Circumference and Hyperuricemia in Normal-Weight Men.","authors":"Wen-Xia Cui, Shi-Wen Wang, Lei Gao, Ding-Huang Mu, Nan Li, Feng-Hui Pan, Wei-Hong Zhou, Yun Hu","doi":"10.2147/DMSO.S493327","DOIUrl":"10.2147/DMSO.S493327","url":null,"abstract":"<p><strong>Purpose: </strong>Hyperuricemia has traditionally been associated with obesity and dyslipidemia. However, the relationship between waist circumference (WC) and hyperuricemia in normal-weight men is still unclear, particularly regarding the roles of triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C). The aim of this research was to explore the mediating roles of TG and HDL-C in the association between WC and hyperuricemia in normal-weight men.</p><p><strong>Methods: </strong>A retrospective observational study was conducted among normal-weight men (18.5 ≤ BMI < 24 kg/m²) aged ≥ 18 years who underwent health checkups in Nanjing from 2021-2023. Relationships between WC, blood lipids, and hyperuricemia were investigated by multivariable regression models and mediation analysis.</p><p><strong>Results: </strong>We enrolled 35,984 participants, with an overall hyperuricemia prevalence of 24.2%. The research found a significant positive association between WC and hyperuricemia in normal-weight men (<i>P</i> < 0.001). For hyperuricemia across rising WC quartiles, with WC divided as follows: Q1 (59 ≤ WC < 77 cm), Q2 (77 ≤ WC < 81 cm), Q3 (81 ≤ WC < 85 cm), and Q4 (85 ≤ WC ≤ 107 cm), the multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were 1.00 (reference), 1.09 (1.01, 1.18), 1.26 (1.15, 1.37), and 1.34 (1.22, 1.46), respectively (all <i>P</i> < 0.001). The mediation analysis indicated that WC had a significant total effect on hyperuricemia (Coefficient = 0.0046, 95% CI: 0.0028, 0.0070, <i>P</i> < 0.001), with significant indirect effects mediated through TG and HDL-C, contributing mediation proportions of 22.3% and 18.3%, respectively (both <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Elevated WC is associated with an increased likelihood of hyperuricemia in normal-weight men. TG and HDL-C play substantial mediating roles in this association. These findings suggest that monitoring WC and lipid profiles in normal-weight men could help identify those at higher risk of hyperuricemia, even in the absence of general obesity.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4599-4610"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burning Tongue and Taste Alteration in Xerostomic Undiagnosed Diabetic Patients with Vitamin D Deficiency.","authors":"Eris Nurul Rahmadhini, Nanan Nur'aeny","doi":"10.2147/DMSO.S492359","DOIUrl":"10.2147/DMSO.S492359","url":null,"abstract":"<p><strong>Background: </strong>Silent diabetes and vitamin D deficiency are difficult to identify because the individual may not even realize they have one. Xerostomia-related burning tongue and taste changes may indicate a systemic condition such as diabetes or vitamin D deficiency.</p><p><strong>Purpose: </strong>This case report analyzes the association between diabetes, vitamin D deficiencies, and xerostomia.</p><p><strong>Case presentation: </strong>A 44-year-old female patient complained of having a burning tongue and had lost taste for a week. Routine blood tests and assessments of the Oral Health Impact Profile-14 (OHIP-14) and Depression Anxiety Stress Scale-21 (DASS-21) showed normal results.</p><p><strong>Case management: </strong>Therapy consists of chlorine dioxide zinc-patented mouthwash, multivitamin, petroleum jelly, and oral hygiene instructions. The symptoms decreased significantly on the second visit, but taste perception did not improve. Another complaint was that the mouth felt dry. The results of the Summated Xerostomia Inventory-Indonesian Version (SXI-ID) and Clinical Oral Dryness Scoring System (CODS) examination showed the patient had mild xerostomia and the unstimulated salivary flow rate was lower than normal. Therapy consists of applying ethyl p-hydroxybenzoate gel, neurotropic vitamins, and blood tests for Hemoglobin A1c (HbA1c) and vitamin D 25 (OH) were advised for further evaluation would be more clear. The third visit showed there were no more complaints of dry mouth, and the taste perception was getting normal. The Unstimulated salivary flow rate and CODS were normal. The patient was diagnosed with diabetes and vitamin D deficiency based on the HbA1c examination results of 11% and vitamin D 25 (OH) of 12.5 ng/mL.</p><p><strong>Conclusion: </strong>Xerostomia can indicate systemic conditions like diabetes and vitamin D deficiency. A comprehensive examination is carried out so the patient can receive optimal treatment.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4585-4592"},"PeriodicalIF":2.8,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Antioxidant Enzyme Polymorphisms with Type 2 Diabetes Mellitus in Jazan Province.","authors":"Mahmoud M Habibullah, Ali Hurubi, Ali O Hakamy, Abbas Ali Jaber Alwadani, Ibrahim Mohammed Atti, Hani Alothaid, Ghalia Shamlan, Mohammed Aldughaim, Yahia A Kaabi, Alaa Alhazmi, Hassan Hamali","doi":"10.2147/DMSO.S493459","DOIUrl":"10.2147/DMSO.S493459","url":null,"abstract":"<p><strong>Introduction: </strong>Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, which results in initiates oxidative stress and disrupts various cellular pathways. In this study, we examined the relationship between polymorphisms in antioxidant enzymes, specifically glutathione peroxidase 1 (GPx1) and catalase (CAT), and the susceptibility to T2DM in a Saudi population from the Jazan Province.</p><p><strong>Methods: </strong>A total of 419 participants were evaluated, including 247 T2DM patients and 172 controls. They were genotyped for the GPx1 Pro198Leu and CAT-262C/T polymorphisms by a PCR-based method.</p><p><strong>Results: </strong>The results indicated that individuals with the CAT T/T genotype had a 60% lower likelihood of developing T2DM compared with those harboring the C/C genotype (uOD 0.4; 95% CI 0.2-0.8, p = 0.04); however, no significant association was observed between the GPx1 polymorphism and T2DM.</p><p><strong>Discussion: </strong>The results suggest that CAT polymorphism may confer a protective effect against T2DM, whereas the GPx1 polymorphism appears not to be a determinant of T2DM susceptibility in this population. Further studies including larger and more diverse cohorts are necessary to validate these results and elucidate the underlying mechanisms. Understanding the genetic factors that contribute to T2DM is essential for developing targeted preventive and therapeutic strategies.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4593-4598"},"PeriodicalIF":2.8,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142778948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Risk Prediction Model for Sarcopenia in Chinese Older Patients with Type 2 Diabetes Mellitus.","authors":"Xinming Wang, Shengnan Gao","doi":"10.2147/DMSO.S493903","DOIUrl":"10.2147/DMSO.S493903","url":null,"abstract":"<p><strong>Purpose: </strong>Sarcopenia is a common prevalent age-related disorder among older patients with type 2 diabetes mellitus (T2DM). This study aimed to develop and validate a nomogram model to assess the risk of incident sarcopenia among older patients with T2DM.</p><p><strong>Patients and methods: </strong>A total of 1434 older patients (≥ 60 years) diagnosed with T2DM between May 2020 and November 2023 were recruited. The study cohort was randomly divided into a training set (n = 1006) and a validation set (n = 428) at the ratio of 7:3. The best-matching predictors of sarcopenia were incorporated into the nomogram model. The accuracy and applicability of the nomogram model were measured by using the area under the receiver operating characteristic curve (AUC), calibration curve, Hosmer-Lemeshow test, and decision curve analysis (DCA).</p><p><strong>Results: </strong>571 out of 1434 participants (39.8%) had sarcopenia. Nine best-matching factors, including age, body mass index (BMI), diabetic duration, glycated hemoglobin A1c (HbA1c), 25 (OH)Vitamin D, nephropathy, neuropathy, nutrition status, and osteoporosis were selected to construct the nomogram prediction model. The AUC values for training and validation sets were 0.800 (95% CI = 0.773-0.828) and 0.796 (95% CI = 0.755-0.838), respectively. Furthermore, the agreement between predicted and actual clinical probability of sarcopenia was demonstrated by calibration curves, the Hosmer-Lemeshow test (<i>P</i> > 0.05), and DCA.</p><p><strong>Conclusion: </strong>Sarcopenia was prevalent among older patients with T2DM. A visual nomogram prediction model was verified effectively to evaluate incident sarcopenia in older patients with T2DM, allowing targeted interventions to be implemented timely to combat sarcopenia in geriatric population with T2DM.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4611-4626"},"PeriodicalIF":2.8,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Acupoint Catgut Embedding on Subjective Appetite in Overweight and Obese Adults with Strong and Moderate Appetite: A Secondary Analysis of a Randomized Clinical Trial.","authors":"Xin Tang, Gaoyangzi Huang, Qifu Li, Siwen Zhao, Ruqin Yang, Hongyang Wang, Yuanzheng Deng, Zili Liu, Taipin Guo, Fanrong Liang","doi":"10.2147/DMSO.S487877","DOIUrl":"10.2147/DMSO.S487877","url":null,"abstract":"<p><strong>Background: </strong>Appetite plays a crucial role in obesity and weight loss outcomes. while conventional therapies reduce appetite, They often have limitations. Acupoint Catgut Embedding (ACE) is widely used for weight loss, but its impact on subjective appetite, especially across different appetite status, remains underexplored.</p><p><strong>Objective: </strong>To evaluate the differential impact of ACE on the subjective appetite of overweight and obese adults with strong and moderate appetites.</p><p><strong>Methods: </strong>This secondary analysis used data from a multicenter, double-blind, parallel randomized clinical trial of the ACE intervention. A total of 122 overweight and obese patients aged 18-60 were randomly assigned to the ACE and Non-acupoint Catgut Embedding (NACE) groups, each receiving six sessions over 12 weeks and a 4-week follow-up. Appetite was measured using the Visual Analogue Scale (VAS), and a generalized linear mixed-effects model assessed changes in appetite scores. Bonferroni corrections were applied for multiple comparisons (<i>P</i> < 0.05).</p><p><strong>Results: </strong>Participants with strong appetite in the ACE group showed a significant reduction in appetite VAS score from 7.78 (0.66) at baseline to 5.00 (0.72) at 16 weeks (<i>P</i> < 0.05), compared to a reduction from 7.97 (0.93) to 6.54 (1.17) in the NACE group. The adjusted relative rate ratio between the two groups was 0.411 (95% CI, 0.210 to 0.534; <i>P</i> < 0.05). In participants with moderate appetite, no significant difference was observed between the two groups (<i>P</i> > 0.05). The significant baseline difference in appetite scores between participants with strong and moderate appetite (<i>P</i> < 0.05) became non-significant by week 16 (<i>P</i> > 0.05).</p><p><strong>Conclusion: </strong>This study reveals the stratified effect of ACE on appetite, with greater reduction in those with strong appetite and no significant change in those with moderate appetite. This suggests ACE reduces appetite effectively without excessive suppression, supporting its potential as a sustainable obesity management strategy.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4573-4583"},"PeriodicalIF":2.8,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Overall Safety of Glucokinase Activators in Patients with Type 2 Diabetes Mellitus.","authors":"Ting-Ting Liang, Min-Jia Cao, Qian Wang, Jia-Shuang Zou, Xiao-Ming Yang, Li-Fang Gu, Fang-Hong Shi","doi":"10.2147/DMSO.S474280","DOIUrl":"10.2147/DMSO.S474280","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the overall clinical adverse events (AEs) associated with glucokinase activators (GKAs) in patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>We searched MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov databases from their dates of inception to June 6, 2023, for randomized controlled trials (RCTs) that reported safety data for GKAs in patients with T2DM. A random-effects model was used to obtain a summary odds ratio (OR) with associated 95% Confidence Intervals (CIs). Pre-specified subgroup analyses were conducted according to individual GKAs (dorzagliatin and all other GKAs), various controls, follow-up duration, mean duration of diabetes, and the location of clinical research.</p><p><strong>Results: </strong>17 RCTs enrolling 4,918 patients (3,196 patients received GKAs and 1,722 patients received placebo or other hypoglycemic drugs) were identified. Among the 17 RCTs, dorzagliatin, AZD1656 and MK-0941 in three trials (1,541 patients), five trials (885 patients), and three trials (798 patients), respectively. GKA treatment was associated with a higher risk of any AEs (OR 1.220, 95% CI 1.072-1.389), mild AEs (OR 1.373, 95% CI 1.085-1.738), hyperlipidemia (OR 1.532, 95% CI 1.071-2.189), and hyperuricemia (OR 2.768, 95% CI 1.562-4.903) compared to patients in the control groups. The higher risks of any AEs were mainly attributed to dorzagliatin and MK-0941 and mild AEs mainly attributed to dorzagliatin. Notably, dorzagliatin had significant effects on the occurrence of hyperlipidemia (OR 1.476, 95% CI 1.025-2.126) and hyperuricemia (OR 2.727, 95% CI 1.523-4.883) in the subgroup analyses. No significant effects were detected from other GKAs when regarding hyperlipidemia and hyperuricemia.</p><p><strong>Conclusion: </strong>The results of our meta-analysis indicated that GKAs were associated with a higher risk of any AEs, mild AEs, hyperlipidemia, and hyperuricemia. Further subgroup analyses revealed that the increased occurrence of hyperlipidemia, and hyperuricemia mainly originated from dorzagliatin treatment.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4539-4552"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Blood Glucose Can Promote Uric Acid Excretion: A Cross-Sectional Study Involving Urinary Glucose and Urinary Uric Acid in China.","authors":"Ya Zhou, Haixiao Wang, Weiyi Gao","doi":"10.2147/DMSO.S472686","DOIUrl":"10.2147/DMSO.S472686","url":null,"abstract":"<p><strong>Purpose: </strong>Uric acid and blood glucose are important indicators of metabolic disorders. Numerous studies have elucidated the association between them, but the focus on their relationship through examination of urinary glucose and uric acid excretion has been limited. In this study, we conducted a comprehensive analysis on these indicators to explain the relationship.</p><p><strong>Patients and methods: </strong>This study involved the recruitment of 2498 patients who underwent fractional excretion of uric acid (FEUA) testing during their hospitalization at the Health Department of Qilu Hospital (Qingdao), Shandong University, between January 2017 and November 2023, with 1416 subjects being included in the final analysis. The included subjects were analyzed based on different genders. One-way analysis of variance, multiple linear regression analysis, and restricted cubic spline were adopted for data analysis.</p><p><strong>Results: </strong>Higher FEUA and lower serum uric acid (SUA) levels were observed in diabetic patients with urinary glucose than in diabetic patients without urinary glucose and the nondiabetic population. FEUA exhibited a proportional increase with elevated blood glucose levels, even including cases that lacked urinary glucose. After adjustment for potential confounding factors, SUA levels did not increase with the increase in fasting blood glucose (FBG) levels, and once FBG levels surpassed a certain threshold leading to glucosuria, FEUA was further elevated, accompanied with a subsequent reduction in SUA levels. There is a stronger linear relationship between SUA or FEUA and FBG levels in women than that in men after adjusting for confounding factors.</p><p><strong>Conclusion: </strong>Hyperglycemia is not considered a risk factor for hyperuricemia. Regardless of the presence of urinary glucose, elevated blood glucose levels can stimulate renal excretion of uric acid. Upon reaching a threshold that induces glucosuria, the SUA levels decrease substantially. Meanwhile, there are some differences in the relationship between SUA or FEUA and FBG among different genders.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4553-4563"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comment on 'Clinical Value of Urinary Wilms' Tumour-1 and Mu-Glutathione S-Transferase Gene Expression in Kidney Injury in Type 2 Diabetes Mellitus: Important Considerations for Clinical Application' [Letter].","authors":"Yong Luo, Zhongying Huang, Jifang Yang","doi":"10.2147/DMSO.S507669","DOIUrl":"https://doi.org/10.2147/DMSO.S507669","url":null,"abstract":"","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4571-4572"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-Existing Ectopic Cortisol-Producing Adenoma and Retroperitoneal Schwannoma, a Rare Case Report.","authors":"Lingfeng Shi, Jiongyu Hu, Xiaoli Xu, Yongquan Wang, Senlin Xu, Lijuan Tu","doi":"10.2147/DMSO.S487334","DOIUrl":"10.2147/DMSO.S487334","url":null,"abstract":"<p><strong>Background: </strong>Ectopic cortisol-producing adrenocortical adenoma (ECPA) is extremely rare, with only a few cases reported. Retroperitoneal schwannoma is also uncommon, accounting for only 0.7-5% of all schwannomas. It is peculiar to have both conditions at the same time, and it is intriguing to explore their possible connection. Herein, we present a case of both ECPA and retroperitoneal schwannoma and provide our conjectures regarding their co-occurrence.</p><p><strong>Case presentation: </strong>A 38-year-old female presented with a two-year history of facial and lower limb edema, as well as chest tightness and palpitations for the past four months. Physical examination revealed hypertension, a high body mass index (BMI), moon face, thick neck and back fat, abdominal obesity, and purple striae on the abdomen. Laboratory tests indicated an persistent increased cortisol level and suppression of adrenocorticotropic hormone (ACTH). Adrenal-enhanced computed tomography (CT) scan showed that both adrenal glands appeared normal without evident adenomas or hyperplasia. However, the scan revealed two lesions located in the right renal hilum and retroperitoneal area positioned anteriorly to the lower margin of the lumbar 2 pyramid. Further imaging using ⁶⁸Ga-DOTATATE PET/CT revealed concentrated radiotracer uptake in the tumor at the right renal hilum, indicating it may be responsible for the patient's Cushing's symptoms. After laparoscopic resection of these masses, clinical symptoms improved significantly. Postoperative pathology confirmed the right renal hilum one lesion as an ECPA while identifying another lesion as a schwannoma.</p><p><strong>Conclusion: </strong>Our literature reported a case with the diagnosis of both ECPA in the right renal hilum and retroperitoneal schwannoma. ⁶⁸Ga-DOTATATE PET/CT imaging can provide functional and locational information on tumors, enabling a comprehensive examination of the entire body to identify lesions that require appropriate treatment.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4565-4570"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acupuncture and Drug Combination Therapy for Abnormal Glucose Metabolism: Exploring Synergistic Enhancement and Reduced Toxicity Mechanisms.","authors":"Xinyi Tian, Wenjun Wang, Lu Zhang, Liuqing Wang, Kaiqi Zhang, Xiaolei Ge, Zhengrong Luo, Yaqian Zhao, Xu Zhai, Chunjing Li","doi":"10.2147/DMSO.S492626","DOIUrl":"https://doi.org/10.2147/DMSO.S492626","url":null,"abstract":"<p><p>This review examines the impact of combining acupuncture with drug therapy on abnormal glucose metabolism and investigates their underlying mechanisms. Conditions like diabetes pose significant health risks due to irregular glucose metabolism. Traditional drug treatments often encounter challenges related to side effects and drug resistance. Acupuncture, as a non-pharmacological intervention, is thought to enhance glucose metabolism and mitigate medication side effects. We selected the relevant studies of acupuncture or electroacupuncture combined with drugs in the treatment of abnormal glucose metabolism in the past five years, and the results indicate that the combination of acupuncture or electroacupuncture and drug therapy markedly enhances glucose metabolism and mitigates medication-related side effects such as gastrointestinal discomfort and hypoglycemia. Overall, this review underscores the synergistic benefits of acupuncture and drug therapy in improving treatment efficacy and reducing adverse effects, offering promising new approaches for managing abnormal glucose metabolism. Our review provides evidence for the potential benefits of combining acupuncture with drug therapy for abnormal glucose metabolism, which could lead to improved treatment outcomes and reduced side effects for patients with type 2 diabetes mellitus.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4525-4537"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}